Back to Search
Start Over
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
- Source :
-
Clinical breast cancer [Clin Breast Cancer] 2020 Jun; Vol. 20 (3), pp. e251-e260. Date of Electronic Publication: 2019 Aug 21. - Publication Year :
- 2020
-
Abstract
- Expression of human epidermal growth factor receptor 2 (HER2) in breast cancer defines a subset of patients (∼15%-20%) who are candidates for anti-HER2 therapies, most notably, trastuzumab, pertuzumab, antibody drug conjugates (eg, T-DM1), and tyrosine kinase inhibitor (TKI) drugs (eg, lapatinib and neratinib), all of which have dramatically changed the prognosis for this aggressive subtype of breast cancer. A roundtable meeting of the Breast Cancer Therapy Expert Group (BCTEG) was convened in March 2018 in an effort to discuss and clarify, from the perspective of the practicing community oncologist, recent developments in the diagnosis and treatment of HER2-positive (HER2 <superscript>+</superscript> ) breast cancer. Members of the group selected 4 key topics for discussion prior to the meeting, including diagnosis of HER2 <superscript>+</superscript> disease, and its treatment in the neoadjuvant, adjuvant, and metastatic settings. Approved testing methods, such as immunohistochemistry and fluorescence in situ hybridization, are used to demonstrate overexpression and/or amplification of HER2 in breast tumors, and established clinical guidelines are used to appropriately define treatment plans for patients with HER2 <superscript>+</superscript> disease. The panel acknowledges a range of treatment options now available for treatment of HER2 <superscript>+</superscript> breast cancer in the neoadjuvant, adjuvant, and advanced/metastatic settings, although it is noted that many controversies remain, including the optimal sequence of therapies, the most appropriate treatment(s) for subsets of patients with HER2 <superscript>+</superscript> disease (eg, hormone receptor-negative or -positive/HER2 <superscript>+</superscript> ), and uncertainties surrounding the diagnosis and definition of HER2 <superscript>+</superscript> disease. The current report summarizes the discussion of the BCTEG panel on this topic.<br /> (Copyright © 2019. Published by Elsevier Inc.)
- Subjects :
- Antineoplastic Agents, Hormonal pharmacology
Antineoplastic Agents, Hormonal therapeutic use
Antineoplastic Agents, Immunological pharmacology
Antineoplastic Agents, Immunological therapeutic use
Antineoplastic Combined Chemotherapy Protocols pharmacology
Biomarkers, Tumor analysis
Biomarkers, Tumor antagonists & inhibitors
Biomarkers, Tumor genetics
Breast pathology
Breast surgery
Breast Neoplasms diagnosis
Breast Neoplasms genetics
Breast Neoplasms mortality
Chemotherapy, Adjuvant methods
Chemotherapy, Adjuvant standards
Consensus
Female
Gene Amplification
Humans
Mastectomy methods
Mastectomy standards
Neoadjuvant Therapy methods
Neoadjuvant Therapy standards
Progression-Free Survival
Protein Kinase Inhibitors pharmacology
Protein Kinase Inhibitors therapeutic use
Receptor, ErbB-2 analysis
Receptor, ErbB-2 antagonists & inhibitors
Receptor, ErbB-2 genetics
Receptors, Estrogen analysis
Receptors, Estrogen antagonists & inhibitors
Receptors, Estrogen metabolism
Receptors, Progesterone analysis
Receptors, Progesterone antagonists & inhibitors
Receptors, Progesterone metabolism
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Biomarkers, Tumor metabolism
Breast Neoplasms therapy
Practice Guidelines as Topic
Receptor, ErbB-2 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1938-0666
- Volume :
- 20
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Clinical breast cancer
- Publication Type :
- Academic Journal
- Accession number :
- 32139271
- Full Text :
- https://doi.org/10.1016/j.clbc.2019.08.001